
"IT MEANS a world of difference for ME."



Amgen 2002 Annual Report

We've always been clear at Amgen about our central

aspiration. We're striving to be the

BEST HUMAN THERAPEUTICS COMPANY.

It is a daring, even daunting goal.

IT MEANS embracing constant change, pursuing innovation wherever it leads.

IT MEANS developing today's opportunities to their fullest, acting with speed and decisiveness.

IT MEANS overcoming challenges when they arise with grace, determination, and courage.

It means delivering on promises made, and committing to promises yet to be envisioned.

- 11 Therapeutic Review
- 20 Selected Products and Product Candidates
- 21 Financial Performance
- 23 Management's Discussion and Analysis of Financial Condition and Results of Operations
- 43 Consolidated Financial Statements
- Report of Ernst & Young LLP, Independent Auditors Corporate Information (inside back cover)

Board of Directors and Executive Officers

BOARD OF DIRECTORS

David Baltimore

President

California Institute of Technology

Frank J. Biondi, Jr.

Senior Managing Director WaterView Advisors LLC

Jerry D. Choate

Retired Chairman and Chief Executive Officer The Allstate Corporation

Edward V. Fritzky

Retired Chairman and Chief Executive Officer

Frederick W. Gluck

Retired Vice Chairman Bechtel Group, Inc

Franklin P. Johnson, Jr.

General Partner

Asset Management Partners

Steven Lazarus

Managing General Partner ARCH Venture Partners, L.P.

Gilbert S. Omenn

Professor of Internal Medicine, Human Genetics and Public Health,

Judith C. Pelham

President and Chief Executive Officer

Trinity Health

Adm. J. Paul Reason, USN (Retired)

President and Chief Operating Officer Metro Machine Corporation

Donald B. Rice

President and
Chief Executive Officer

Kevin W. Sharer

Chairman of the Board, Chief Executive Officer and President Amgen Inc.

Patricia C. Sueltz

Executive Vice President Software Systems Group Sun Microsystems, Inc.

EXECUTIVE OFFICERS

Fabrizio Bonanni

Senior Vice President Ouality and Compliance

Hassan Dayem

Senior Vice President and Chief Information Officer

Dennis M. Fenton

Executive Vice President Process Development, Operations and Quality

Brian M. McNamee

Senior Vice President Human Resources Joseph P. Miletich

Senior Vice President, Research and Preclinical Development

George J. Morrow

Executive Vice President Worldwide Sales and Marketing

Richard D. Nanula

Executive Vice President, Finance, Strategy and Communications, and Chief Financial Officer

Steven M. Odre

Senior Vice President General Counsel and Secretary

Roger M. Perlmutter

Executive Vice President Research and Development

Beth C. Seidenberg

Senior Vice Presider
Development

Kevin W. Sharer

Chairman of the Board, Chief Executive Officer and Presiden

Stockholder Information

Corporate Office

One Amgen Center Drive Thousand Oaks, California 91320-1799 (805) 447-1000

SEC Form 10-K

A copy of the Company's Annual Report on Form 10-K for the year ended December 31, 2002, filed with the Securities and Exchange Commission, is available without charge upon written request to Corporate Secretary, Amgen, One Amgen Center Drive, Thousand Oaks, California 91320-1799; by calling (800) 84-AMGEN; or by accessing the Company's website at www.amgen.com.

Transfer Agent and Registrar

American Stock Transfer & Trust Company 59 Maiden Lane

New York, New York 10038

Stockholder Inquiries

Inquiries related to stock transfers or lost certificates should be directed to American Stock Transfer & Trust Company, (800) 937-5449 or (212) 936-5100. General information regarding the Company and recent news releases can be obtained by contacting Amgen's automated stockholder information line at (800) 84-AMGEN or by accessing the Company's website at www.amgen.com.

Independent Auditors

Ernst & Young LLP, Los Angeles, California

Annual Meeting

The Annual Meeting will be held on Thursday, May 15, 2003, at 10:30 a.m. at the Omni Interlocken Resort, 500 Interlocken Blvd., Broomfield, Colorado

Price Range of Common Stock

The Company's common stock trades on The NASDAQ Stock Market under the symbol AMGN. No cash dividends have been paid on the common stock to date, and the Company currently intends to retain any earnings for development of the Company's business and for repurchases of its common stock.

The following table sets forth, for the fiscal periods indicated, the range of high and low closing sales prices of the common stock as quoted on The NASDAQ Stock Market for the years 2002 and 2001:

	2002		2001	
	High	Low	High	Low
4th Quarter	\$51.75	\$43.66	\$68.49	\$56.03
3rd Quarter	48.54	31.07	65.66	54.01
2nd Quarter	61.39	37.80	70.02	51.51
1st Quarter	62.48	54.33	74.19	54.94

Trademarks Listed in This Report

Amgen, Aranesp®, EPOGEN®, Kineret®, Neulasta[™], and NEUPOGEN® are trademarks of Amgen Inc. ENBREL[®] is a trademark of Amgen's subsidiary. Immunex Corporation.

Hotlines

Customer Service Hotline (800) 28-AMGEN Investor Materials Hotline (800) 84-AMGEN Jobline (800) 446-4007 Medical Information Connection (800) 77-AMGEN Reimbursement Hotline (800) 272-9376 Clinical Safety Hotline (800) 835-2879



Amgen Inc. One Amgen Center Drive Thousand Oaks, CA 91320-1799

www.amgen.com